Drug for treating urolithiasis-related disease, and preparation method therefor

A method for treating urolithiasis and urinary tract infections or kidney damage caused by urolithiasis in a subject, wherein the method comprises administering to the subject an effective amount of the pharmaceutically active ingredient extract extracted from the plant Polygala japonica Houtt, or as an adjuvant drug after surgical treatment of urolithiasis, and

• wherein the extract comprises:
• (a) one or more flavonol compounds selected from the compounds of the following general formula (F-7K), (F-7Q), (F-74Q), (F-K), (F-Q), and (F-74K) as the first active ingredient:
• wherein,
• R9 is selected from the group consisting of —OH, —O-Glc, —O-Gal, —O-Glc-Glc, —O-Glc-Gal, —O-Glc-Rha, —O-Gal-Glc, —O-Gal-Gal, —O-Gal-Rha, —O-Glc-Glc-Api, —O-Gal-Glc-Api, —O-Glc-Gal-Api, and —O-Gal-Gal-Api,
• wherein,
• R10 is selected from the group consisting of —OH, —O-Glc, —O-Gal, —O-Glc-Glc, —O-Glc-Gal, —O-Glc-Api, —O-Glc-Rha, —O-Gal-Glc, —O-Gal-Gal, —O-Gal-Api, —O-Gal-Rha, —O-Glc-Glc-Api, —O-Gal-Glc-Api, —O-Glc-Gal-Api, —O-Gal-Gal-Api, —O-Gal-Rha-Gal, —O-Gal-Rha-Glc, —O-Glc-Rha-Glc, and —O-Glc-Rha-Gal,
• wherein,
• R12 is selected from the group consisting of —OH, —O-Glc, —O-Gal, —O-Glc-Api, —O-Gal-Api,
• wherein,
• R13 is selected from the group consisting of —OH, —O-Glc, —O-Gal, —O-Glc-Rha, and —O-Gal-Rha,
• wherein,
• R11 is selected from the group consisting of —OH, —O-Gal, and —O-Gal-Api;
• and
• wherein the total content of the flavonol compound of the first active ingredient (a) accounts for 75-100% of the total extract of Polygala japonica Houtt, wherein the component content (%) is the HPLC % content calculated by using the HPLC integral area normalization method according to the common method in the art.